Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sarcoma survival: does guideline care make the difference?

NCT ID NCT07864870

Knowledge-focused Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 08, 2026 · Last updated Oct 09, 2026 · Updated 1 time

Summary

Researchers at a French hospital are reviewing medical records of about 900 adults treated for soft tissue sarcoma to see how closely their care matched international guidelines. The study compares patients treated between 2010 and 2016 with those treated between 2017 and 2024. It asks whether better adherence to recommended practices is linked to longer overall survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If guideline adherence tracks with longer survival, this could strengthen the case for standardizing sarcoma care at hospitals everywhere.
What could go wrong
This is a retrospective look at records from one hospital, so it can show patterns but cannot prove that following guidelines causes better survival. Findings may not apply to other centers or patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 900 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with suspected or confirmed soft tissue sarcoma presented at multidisciplinary tumor boards in Strasbourg between 2017 and 2024

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient aged 18 years or older at first multidisciplinary tumor board presentation * Presented for multidisciplinary tumor board evaluation for soft tissue or visceral tumor * First presentation between 01/01/2017 and 31/12/2024 * Absence of opposition to reuse of medical data for research purposes Exclusion Criteria: * Presence of opposition to reuse of medical data for research purposes * Patient younger than 18 years at first presentation * Bone tumors, gastrointestinal stromal tumors (GIST), or Kaposi sarcoma * First presentation outside the study period * Management outside Alsace-Moselle * Duplicate records

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Soft tissue sarcoma (STS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Soft tissue sarcoma (STS)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Service d'hématologie-oncologie pédiatrique - CHU de Strasbourg - France

    RECRUITING

    Strasbourg, 67091, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.